CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Metformin Hydrochloride +1 moredrug
Likely dose
Metformin Hydrochloride 2500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03733132
NCT03733132Phase 2Completed
CompareCT.gov

Metformin Effect on Brain Function in Insulin Resistant Elderly People

Mayo Clinic·interventional·Posted Nov 7, 2018·Updated Jun 18, 2024

In Brief

A Phase 2 clinical trial evaluating Metformin Hydrochloride and Placebo Oral Tablet for Insulin Resistance and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

Alzheimer's disease (AD) and other forms of dementia are rapidly increasing with the aging of the population, and show a clear preponderance among people with insulin resistance. Metformin, an insulin sensitizer, is being examined in clinical trials as an anti-aging drug. However, very little objective data is available regarding metformin's effect on the brain, a major organ affected by aging.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsulin Resistance, Obesity, Obesity, Abdominal
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 7, 2018
Enrollment StartMar 15, 2019
Primary CompletionApr 5, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.7 years ago

Interventions

Metformin Hydrochloridedrug

Metformin treatment of 2500mg for 10 months in the Metformin group

Placebo Oral Tabletdrug

Placebo treatment of identical tablets to metformin group